Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

COSIMO Cancer Associated Thrombosis - Patient Reported Outcomes With Rivaroxaban. A Non-interventional Study on Patients Changing to Xarelto® for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer.

NCT02742623 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT02742623
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02742623 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
COSIMO Cancer Associated Thrombosis - Patient Reported Outcomes With Rivaroxaban. A Non-interventional Study on Patients Changing to Xarelto® for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer.
Lead sponsor
Bayer
Phase
Observational
Overall status
Completed
Start date
October 11, 2016
Completion date
March 28, 2019
Enrollment
528 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

venous thrombosis and pulmonary embolism